tiprankstipranks
Matinas BioPharma (DE:6LJ)
FRANKFURT:6LJ

Matinas BioPharma Stock Price & Analysis

0 Followers

6LJ Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€0.49 - €1.26
Previous Close€0.67
Volume0.00
Average Volume (3M)7.53K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)€38.50M
Total Debt (Recent Filing)€3.51M
P/E RatioN/A
Beta0.55
Next EarningsNov 16, 2022
EPS Estimate-€0.03
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)N/A
Shares Outstanding216,864,526
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume1,050
30 Day Avg. Volume7,528
P/B Ratio3.72
P/S Ratio136.67
P/CF RatioN/A
P/FCF Ratio-9.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside364.30% Upside
Rating ConsensusStrong Buy
AlphaN/A
Number of Analyst Covering3


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

6LJ FAQ

What was Matinas BioPharma’s price range in the past 12 months?
Matinas BioPharma lowest stock price was €0.49 and its highest was €1.26 in the past 12 months.
    What is Matinas BioPharma’s market cap?
    Currently, no data Available
    When is Matinas BioPharma’s upcoming earnings report date?
    Matinas BioPharma’s upcoming earnings report date is Nov 16, 2022 which is in 45 days.
      How were Matinas BioPharma’s earnings last quarter?
      Matinas BioPharma released its earnings results on Aug 11, 2022. The company reported -€0.031 earnings per share for the quarter, beating the consensus estimate of -€0.035 by €0.004.
        Is Matinas BioPharma overvalued?
        According to Wall Street analysts Matinas BioPharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Matinas BioPharma pay dividends?
          Matinas BioPharma does not currently pay dividends.
          What is Matinas BioPharma’s EPS estimate?
          Matinas BioPharma’s EPS estimate is -€0.03.
            How many shares outstanding does Matinas BioPharma have?
            Currently, no data Available
            What happened to Matinas BioPharma’s price movement after its last earnings report?
            Matinas BioPharma reported an EPS of -€0.031 in its last earnings report, beating expectations of -€0.035. Following the earnings report the stock price went down -7.075%.
              Which hedge fund is a major shareholder of Matinas BioPharma?
              Currently, no hedge funds are holding shares in DE:6LJ

              ---

              Matinas BioPharma Stock Analysis

              Smart ScoreNeutral
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10
              7

              Analyst Consensus

              Strong Buy
              Average Price Target: €3.06

              Blogger Sentiment

              N/A
              Currently Not Enough Data Available

              Insider Transactions

              N/A
              Currently Not Enough Data Available

              News Sentiment

              N/A
              Currently Not Enough Data Available

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -51.07%
              12-Months-Change

              Fundamentals

              Return on Equity
              -48.11%
              Trailing 12-Months
              Asset Growth
              -25.09%
              Trailing 12-Months
              The Matinas BioPharma Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
              Learn more about TipRanks Smart Score

              Company Description

              Matinas BioPharma

              Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.

              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              AbbVie
              Amgen
              Gilead Sciences
              Moderna
              Vertex Pharmaceuticals

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis